Status asthmaticus (acute severe asthma) is defined as severe asthma unresponsive to repeated courses of beta-agonist therapy, representing a medical emergency that requires immediate recognition and aggressive treatment. [1-2] Approximately 25,000–50,000 patients per year require ICU admission in the United States for life-threatening asthma. [3]
The following figure outlines the acute care management algorithm per GINA guidelines:
1. History
- Onset and progression: Rapid vs. gradual onset (sudden-onset attacks carry higher mortality); duration of current symptoms; what triggered the episode
- Symptom characterization: Dyspnea severity, chest tightness, cough, inability to speak in full sentences, inability to lie flat, air hunger [1][5]
- Current medications: ICS use and adherence, SABA frequency (>8 puffs in prior 24 hours is a red flag), recent OCS use or withdrawal [5-6]
- Asthma morbidity history: Prior intubations, ICU admissions, ED visits, hospitalizations — these are the strongest predictors of asthma-related death [1][5]
- Triggers: Viral URI (~50% of episodes), allergen exposure (pets, mold/Alternaria), NSAID use in aspirin-sensitive patients, irritant inhalation (smoke, paint), exercise, medication nonadherence [1-2]
- Important negatives: Fever, purulent sputum, unilateral symptoms, chest pain, leg swelling, choking episode (to exclude mimics)
2. Alarm Features
- Drowsiness, confusion, or altered mental status — cerebral hypoxemia, impending arrest [5-6]
- Silent chest on auscultation — minimal ventilation, insufficient airflow to generate wheeze [5][7]
- Inability to speak or speak only in single words [1]
- Refusal to recline <30° [1-2]
- SpO₂ <92% on presentation (before treatment) — associated with high morbidity and likely need for hospitalization [6]
- Cyanosis, diaphoresis, accessory muscle use [5]
- Normalizing PaCO₂ in a tachypneic patient — indicates respiratory muscle fatigue and impending failure [7]
- Pulsus paradoxus >25 mmHg [2]
- Failure to respond to initial aggressive bronchodilator therapy [1]
3. Medications
First-line treatments:
- Inhaled SABA (albuterol): Adults — 2.5–5 mg nebulized q20min × 3 doses, then 2.5–10 mg q1–4h; or continuous nebulization 10–15 mg/hr. Children — 0.15 mg/kg (min 2.5 mg) q20min × 3 [4]
- Ipratropium bromide: 0.5 mg nebulized q20min × 3 doses (adults); 0.25–0.5 mg (children). Reduces ED time and hospitalization rates; benefit not sustained after admission [1][4]
- Systemic corticosteroids: Adults — prednisone/methylprednisolone 40–80 mg/day; children — 1–2 mg/kg/day (max 60 mg). Administer within the first hour; clinical benefit takes 6–12 hours [1][4][8]
- Oxygen: Target SpO₂ 93–95% in adults/adolescents. Avoid excessive O₂ which may worsen hypercapnia [4]
Second-line/adjunctive:
- IV magnesium sulfate: 2 g over 20 minutes (adults); modestly reduces hospitalizations in severe exacerbations [4]
- High-dose ICS: ≥2 mg beclomethasone equivalent within the first hour may reduce need for hospitalization [4]
- IM epinephrine: For anaphylaxis-associated asthma or severe refractory cases; adults 0.3–0.5 mg, children 0.01 mg/kg [4]
Refractory/ICU-level therapies:
- IV terbutaline or epinephrine for refractory bronchospasm [7][9]
- Ketamine: 0.5–2 mg/kg/h continuous infusion; bronchodilator and anti-inflammatory properties; preferred induction agent if intubation needed. Evidence for routine use is limited [7][10-11]
- Heliox (70:30 or 80:20 He:O₂): Reduces airway resistance; may improve nebulized drug delivery. Not routinely recommended but may be considered as rescue therapy [7]
- Inhaled anesthetics (sevoflurane, isoflurane): Last-line for intubated patients with refractory bronchospasm; requires anesthesiology involvement [7][12]
Medication cautions:
- Avoid beta-blockers (including ophthalmic)
- NSAIDs contraindicated in aspirin-exacerbated respiratory disease
- Avoid sedatives/anxiolytics in non-intubated patients (risk of respiratory depression)
- Prolonged neuromuscular blockade + corticosteroids → risk of critical illness myopathy [13]
4. Diet
- NPO if severe/critical and intubation is possible
- Hydration: Many patients are dehydrated from tachypnea, diaphoresis, and poor oral intake; IV fluid resuscitation is important, especially before positive-pressure ventilation (risk of hypotension) [14]
- Long-term: Identify and avoid known food allergens (food allergy is a risk factor for asthma-related death); sulfite-containing foods/beverages may trigger bronchospasm in susceptible individuals [5]
5. Review of Systems
- Pulmonary: Cough, wheeze, dyspnea, sputum production, hemoptysis
- Cardiac: Chest pain, palpitations (beta-agonist effects, consider PE or cardiac mimics)
- ENT: Nasal congestion, postnasal drip, sore throat (URI trigger, vocal cord dysfunction)
- GI: GERD symptoms (trigger for asthma)
- Psychiatric: Anxiety, panic (both a mimic and comorbidity)
- Allergic/Immunologic: Recent allergen exposures, anaphylaxis symptoms (urticaria, angioedema)
6. Collateral History and Family History
- Collateral: Confirm medication adherence, actual inhaler technique, home nebulizer use, recent controller changes, prior action plan compliance
- Family history: Asthma, atopy, eczema, allergic rhinitis, sudden cardiac death
- Social context: Smoking/vaping, secondhand smoke, occupational exposures, illicit drug use (cocaine can cause bronchospasm), housing conditions (mold, pests), psychiatric disorders, dysfunctional family settings in children — all risk factors for asthma-related death [5]
7. Risk Factors
Risk factors for asthma-related death: [5-6]
- Prior intubation or ICU admission for asthma
- ≥2 hospitalizations or ≥3 ED visits in the past year
- SABA overuse (>1 canister/month)
- Poor adherence to or absence of ICS therapy
- Recent OCS withdrawal
- Food allergy in an atopic individual
- Psychiatric disorders, illicit drug use
- Low socioeconomic status, limited healthcare access
Common triggers: [1-2]
- Viral respiratory infections (~50%)
- Allergen exposure (pets, mold, dust mites, pollen)
- NSAID/aspirin in sensitive patients
- Irritant inhalation (smoke, chemicals)
- Exercise, cold air
- Medication nonadherence
8. Differential Diagnosis
- Anaphylaxis — urticaria, angioedema, hypotension; administer epinephrine
- Vocal cord dysfunction (VCD) — inspiratory stridor, flattened inspiratory loop on flow-volume curve
- Foreign body aspiration — sudden onset, unilateral wheeze, especially in children
- Pulmonary embolism — pleuritic chest pain, risk factors, unilateral leg swelling
- Pneumothorax/tension pneumothorax — sudden pleuritic pain, unilateral absent breath sounds; critical in mechanically ventilated patients [15]
- Decompensated heart failure/pulmonary edema — "cardiac asthma," orthopnea, JVD, crackles
- COPD exacerbation — older patients, smoking history
- Pneumonia/lower respiratory tract infection — fever, productive cough, focal findings
- Epiglottitis/upper airway obstruction — stridor, drooling, toxic appearance
- Hyperventilation syndrome/panic attack — perioral/extremity paresthesias, normal SpO₂ [5]
9. Past Medical History
- Prior asthma severity: Frequency of exacerbations, prior intubations, ICU admissions, near-fatal episodes
- Comorbidities: Allergic rhinitis, nasal polyps, GERD, obesity, OSA, eczema, aspirin-exacerbated respiratory disease
- Surgical history: Prior ENT surgery (polyps), prior tracheostomy
- Chronic medications: Current controller regimen, biologic therapy, OCS dependence
10. Physical Exam
Vital signs:
- Allergy and Asthma Proceedings + 1[1-2]
Focused exam:
- General: Tripod positioning, inability to speak in sentences, diaphoresis, agitation vs. obtundation
- Lungs: Diffuse expiratory wheezing → progressing to silent chest (ominous); prolonged expiratory phase; air trapping [5][7]
- Accessory muscles: SCM, intercostal, subcostal, supraclavicular retractions [1]
- Cardiac: Tachycardia, assess for pulsus paradoxus
- Skin: Cyanosis (late finding), urticaria/angioedema (anaphylaxis)
- ENT: Nasal polyps, nasal congestion, oropharyngeal edema
11. Lab Studies
- ABG/VBG: Not routine; obtain if SpO₂ <90–92% or signs of severe exacerbation. Expect initial respiratory alkalosis → normalizing or rising PaCO₂ is ominous (muscle fatigue) → respiratory/metabolic acidosis in severe cases [5][7]
- Basic metabolic panel: Hypokalemia (from beta-agonists and corticosteroids), hyperglycemia
- Lactate: May be elevated from respiratory distress and beta-agonist use
- Troponin: Consider in adults with chest pain or cardiac risk factors; may be elevated in children on continuous albuterol (24% in one study) [16]
- CBC: Leukocytosis may be from steroids or stress; eosinophilia suggests allergic component
- Magnesium level: Check before/after IV magnesium
- Blood gas monitoring: Serial if intubated or critically ill
12. Imaging
- Chest X-ray: Not routinely recommended in uncomplicated exacerbations. Obtain if: [4-5]
- Suspected pneumothorax, pneumomediastinum
- Fever or focal findings suggesting pneumonia
- Foreign body concern
- Failure to respond to treatment
- Subcutaneous emphysema on exam
- Expected findings: Hyperinflation, flattened diaphragms, peribronchial thickening
- Concerning findings: Pneumothorax, pneumomediastinum, lobar consolidation, atelectasis from mucus plugging
- CT chest: Rarely needed acutely; consider for PE (CTA) or if alternative diagnosis suspected
13. Special Tests
- Peak expiratory flow (PEF) / FEV₁: Objective severity assessment; more reliable than symptoms. Pre-treatment <25% predicted → hospitalization recommended; post-treatment >60% predicted → consider discharge [6][17]
- Pediatric Asthma Score (PAS): Bedside scoring tool for children 2–18 years assessing RR, O₂ requirements, auscultation, retractions, and dyspnea (score 5–15) [6]
- PRAM and PASS scores: Validated for pediatric exacerbation severity [6]
- Point-of-care ultrasound: Assess for pneumothorax (absent lung sliding), pleural effusion, cardiac function (RV strain)
- Capnography (ETCO₂): Useful for monitoring ventilation trends; rising ETCO₂ suggests worsening obstruction
14. ECG
Indications: Obtain in severe exacerbations, patients on continuous albuterol, cardiac symptoms, or ICU-level care.
Common findings: [16][18-20]
- Sinus tachycardia — most common; beta-agonist effect and sympathetic drive
- Right axis deviation, P pulmonale (peaked P waves in II, III, aVF) — from acute RV strain/pulmonary hyperinflation [19]
- Low voltage QRS — from hyperinflation
- ST-segment depression/T-wave inversions (especially inferior leads) — seen in 30% of children on continuous albuterol; correlates with severity; usually reversible [16][20]
- Premature ventricular contractions (PVCs) — more common with beta-agonist use [18]
- SVT — rare but reported with high-dose SABA, especially in children [21]
- QTc prolongation — monitor with hypokalemia and high-dose beta-agonists
Dangerous patterns: New arrhythmia, wide-complex tachycardia, ST elevation (consider tension pneumothorax, myocardial ischemia)
15. Assessment
Severity stratification:
- A normalizing PaCO₂ in a tachypneic patient indicates impending respiratory failure [7]
- Clinical status and lung function 1 hour after treatment are more reliable predictors of outcome than status on arrival [6][17]
- Complications: pneumothorax, pneumomediastinum, atelectasis from mucus plugging, respiratory arrest, cardiac arrest from hypoxia/hyperinflation
16. Treatment Plan
Initial stabilization (first 60 minutes):
- Continuous albuterol nebulization (10–15 mg/hr) or MDI 4–10 puffs q20min × 3
- Ipratropium 0.5 mg nebulized q20min × 3 doses
- Systemic corticosteroids within the first hour (prednisone 40–80 mg PO or methylprednisolone 125 mg IV)
- Oxygen to target SpO₂ 93–95%
- IV magnesium sulfate 2 g over 20 minutes if severe/refractory [4][8]
Escalation for refractory cases:
- IV access, continuous monitoring, IV fluids (anticipate dehydration) [14]
- IV terbutaline or epinephrine drip [7]
- Heliox-driven nebulization if available [7]
- NIV (BiPAP): May reduce need for intubation; use in cooperative patients [3][22]
- Ketamine infusion: 0.5–2 mg/kg/h; consider for sedation and bronchodilation [7][11]
If intubation required: [3][7][23-24]
- Induction: Ketamine (1–2 mg/kg IV) preferred for bronchodilatory properties; avoid histamine-releasing agents
- Paralysis: Succinylcholine or rocuronium
- Ventilator strategy: Permissive hypercapnia is standard
- Low RR (8–12 breaths/min), Vt 6–8 mL/kg
- Prolonged expiratory time (I:E ratio ≥1:3–1:4)
- Low PEEP (titrate to intrinsic PEEP)
- Plateau pressure <25–30 cmH₂O, peak pressure <40 cmH₂O
- Tolerate pH >7.2 and elevated PaCO₂
- Sedation: Ketamine or propofol (both have bronchodilatory properties) [3]
- Neuromuscular blockade: Use sparingly; risk of critical illness myopathy with concurrent steroids [13]
- Last-line: Inhaled anesthetics (sevoflurane/isoflurane), ECMO for refractory respiratory failure (survival 83.5–100%) [7][15]
17. Disposition
ICU admission criteria: [3-4][14]
- Drowsiness, confusion, or silent chest
- Requiring intubation or NIV
- Persistent hypoxia (SpO₂ <90%) despite treatment
- Worsening or no improvement after 1–2 hours of aggressive therapy
- Hemodynamic instability
- Need for continuous IV bronchodilators
Hospital admission criteria: [4][6]
- Pre-treatment FEV₁/PEF <25% predicted
- Post-treatment FEV₁/PEF <40% predicted
- Persistent oxygen requirement
- Inadequate response to bronchodilators after 1–3 hours
- Prior intubation or recent hospitalization for asthma
- 8 SABA puffs in prior 24 hours
Discharge criteria: [4][6]
- Symptom improvement with sustained response
- Post-treatment FEV₁/PEF >60% predicted
- SpO₂ >94% on room air
- Able to tolerate oral medications
- Adequate social support and follow-up access
Specialist consultation triggers: Pulmonology, allergy/immunology for recurrent severe exacerbations; anesthesiology for inhaled anesthetics; surgery/ECMO team for refractory cases
18. Follow Up / Return Precautions
Follow-up timing:
- Adults/adolescents: 2–7 days after ED discharge [4]
- Children: 1–2 working days [4]
- Post-hospitalization: Within 1 week; reassess at 1–3 months
Discharge prescriptions:
- OCS: Prednisone 40–50 mg/day × 5–7 days (adults); 1–2 mg/kg/day × 3–5 days (children) [4][8]
- Initiate or step up ICS before discharge [4]
- Ensure rescue inhaler with spacer
- Provide written asthma action plan
Return precautions — instruct patients to seek immediate care for:
- Worsening shortness of breath or inability to speak
- No improvement with rescue inhaler
- Chest pain or palpitations
- Confusion, drowsiness, or blue lips
- Fever with worsening respiratory symptoms
Patient counseling:
- Medication adherence (ICS is the cornerstone of prevention)
- Proper inhaler technique
- Allergen avoidance and trigger identification
- Smoking/vaping cessation
- Ensure follow-up with PCP and/or specialist for long-term asthma management and step-up therapy evaluation [4]
References
1. Acute Severe Asthma (Status Asthmaticus). — Agnihotri NT, Saltoun C. Allergy and Asthma Proceedings. 2019.
2. Acute Severe Asthma (Status Asthmaticus). — Agnihotri NT, Saltoun C. Allergy and Asthma Proceedings. 2019.
3. Acute Severe Asthma (Status Asthmaticus). — Agnihotri NT, Saltoun C. Allergy and Asthma Proceedings. 2019.
4. Chapter 14: Acute Severe Asthma (Status Asthmaticus). — Shah R, Saltoun CA. Allergy and Asthma Proceedings. 2012.
5. Chapter 14: Acute Severe Asthma (Status Asthmaticus). — Shah R, Saltoun CA. Allergy and Asthma Proceedings. 2012.
6. Management of Life-Threatening Asthma: Severe Asthma Series. — Garner O, Ramey JS, Hanania NA. Chest. 2022.
7. Management of Life-Threatening Asthma: Severe Asthma Series. — Garner O, Ramey JS, Hanania NA. Chest. 2022.
8. Acute Asthma Exacerbations: Management Strategies. — Dabbs W, Bradley MH, Chamberlin SM. American Family Physician. 2024.
9. Acute Asthma Exacerbations: Management Strategies. — Dabbs W, Bradley MH, Chamberlin SM. American Family Physician. 2024.
10. Asthma. — Papi A, Brightling C, Pedersen SE, Reddel HK. Lancet. 2018.
11. Asthma. — Papi A, Brightling C, Pedersen SE, Reddel HK. Lancet. 2018.
12. 2025 Global Strategy for Asthma Management and Prevention. — Helen Reddel, Eric Bateman, Gerard FitzGerald, et al Global Initiative for Asthma. 2025.
13. 2025 Global Strategy for Asthma Management and Prevention. — Helen Reddel, Eric Bateman, Gerard FitzGerald, et al Global Initiative for Asthma. 2025.
14. ATS Pediatric Core Curriculum 2024: The Role of the Pediatric Pulmonologist in the Intensive Care Unit. — Leon-Astudillo C, Prero MY, Dy FJ, et al. Pediatric Pulmonology. 2025.
15. ATS Pediatric Core Curriculum 2024: The Role of the Pediatric Pulmonologist in the Intensive Care Unit. — Leon-Astudillo C, Prero MY, Dy FJ, et al. Pediatric Pulmonology. 2025.
16. 2024 Summary Guide for Asthma Management and Prevention. — Helen Reddel, Arzu Yorgancioglu, Mark L. Levy, Rebecca Decker, Kristi Ruey Global Initiative for Asthma. 2024.
17. 2024 Summary Guide for Asthma Management and Prevention. — Helen Reddel, Arzu Yorgancioglu, Mark L. Levy, Rebecca Decker, Kristi Ruey Global Initiative for Asthma. 2024.
18. Pharmacological Management of Pediatric Critical Asthma. — Rogerson CM, White BR, Abu-Sultaneh S. Respiratory Care. 2025.
19. Pharmacological Management of Pediatric Critical Asthma. — Rogerson CM, White BR, Abu-Sultaneh S. Respiratory Care. 2025.
20. Use of Ketamine in Patients With Refractory Severe Asthma Exacerbations: Systematic Review of Prospective Studies. — La Via L, Sanfilippo F, Cuttone G, et al. European Journal of Clinical Pharmacology. 2022.
21. Use of Ketamine in Patients With Refractory Severe Asthma Exacerbations: Systematic Review of Prospective Studies. — La Via L, Sanfilippo F, Cuttone G, et al. European Journal of Clinical Pharmacology. 2022.
22. Use of Ketamine in Asthmatic Children to Treat Respiratory Failure Refractory to Conventional Therapy. — Rock MJ, Reyes de la Rocha S, L'Hommedieu CS, Truemper E. Critical Care Medicine. 1986.
23. Use of Ketamine in Asthmatic Children to Treat Respiratory Failure Refractory to Conventional Therapy. — Rock MJ, Reyes de la Rocha S, L'Hommedieu CS, Truemper E. Critical Care Medicine. 1986.
24. Severe Status Asthmaticus: Management With Permissive Hypercapnia and Inhalation Anesthesia. — Mutlu GM, Factor P, Schwartz DE, Sznajder JI. Critical Care Medicine. 2002.
25. Severe Status Asthmaticus: Management With Permissive Hypercapnia and Inhalation Anesthesia. — Mutlu GM, Factor P, Schwartz DE, Sznajder JI. Critical Care Medicine. 2002.
26. The Assessment and Management of Adults With Status Asthmaticus. — Corbridge TC, Hall JB. American Journal of Respiratory and Critical Care Medicine. 1995.
27. The Assessment and Management of Adults With Status Asthmaticus. — Corbridge TC, Hall JB. American Journal of Respiratory and Critical Care Medicine. 1995.
28. Evaluation and Management of the Critically Ill Adult Asthmatic in the Emergency Department Setting. — Long B, Lentz S, Koyfman A, Gottlieb M. The American Journal of Emergency Medicine. 2021.
29. Evaluation and Management of the Critically Ill Adult Asthmatic in the Emergency Department Setting. — Long B, Lentz S, Koyfman A, Gottlieb M. The American Journal of Emergency Medicine. 2021.
30. Part 10: Adult and Pediatric Special Circumstances of Resuscitation: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Cao D, Arens AM, Chow SL, et al. Circulation. 2025.
31. Part 10: Adult and Pediatric Special Circumstances of Resuscitation: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Cao D, Arens AM, Chow SL, et al. Circulation. 2025.
32. Diastolic Hypotension, Troponin Elevation, and Electrocardiographic Changes Associated With the Management of Moderate to Severe Asthma in Children. — Fagbuyi DB, Venkataraman S, Ralphe JC, et al. Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine. 2016.
33. Diastolic Hypotension, Troponin Elevation, and Electrocardiographic Changes Associated With the Management of Moderate to Severe Asthma in Children. — Fagbuyi DB, Venkataraman S, Ralphe JC, et al. Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine. 2016.
34. 2023 GINA Report, Global Strategy for Asthma Management and Prevention. — Helen K. Reddel, Leonard B. Bacharier, Eric D. Bateman, et al Global Initiative for Asthma. 2023.
35. 2023 GINA Report, Global Strategy for Asthma Management and Prevention. — Helen K. Reddel, Leonard B. Bacharier, Eric D. Bateman, et al Global Initiative for Asthma. 2023.
36. Cardiac Arrhythmias in Adult Patients With Asthma. — Warnier MJ, Rutten FH, Kors JA, et al. The Journal of Asthma : Official Journal of the Association for the Care of Asthma. 2012.
37. Cardiac Arrhythmias in Adult Patients With Asthma. — Warnier MJ, Rutten FH, Kors JA, et al. The Journal of Asthma : Official Journal of the Association for the Care of Asthma. 2012.
38. Reversible Electrocardiographic Changes in Severe Acute Asthma. — Siegler D. Thorax. 1977.
39. Reversible Electrocardiographic Changes in Severe Acute Asthma. — Siegler D. Thorax. 1977.
40. Reversible T-Wave Abnormality in Severe Acute Asthma: An Electrocardiographic Sign of Severity. — Efthimiou J, Hassan AB, Ormerod O, Benson MK. Respiratory Medicine. 1991.
41. Reversible T-Wave Abnormality in Severe Acute Asthma: An Electrocardiographic Sign of Severity. — Efthimiou J, Hassan AB, Ormerod O, Benson MK. Respiratory Medicine. 1991.
42. Supraventricular tachycardia diagnosis in asthma patients is associated with adverse health outcomes. — Markus H, Ceneviva GD, Thomas NJ, Krawiec C. Pediatric Pulmonology. 2024.
43. Supraventricular tachycardia diagnosis in asthma patients is associated with adverse health outcomes. — Markus H, Ceneviva GD, Thomas NJ, Krawiec C. Pediatric Pulmonology. 2024.
44. Emergency Treatment of Asthma. — Lazarus SC. The New England Journal of Medicine. 2010.
45. Emergency Treatment of Asthma. — Lazarus SC. The New England Journal of Medicine. 2010.
46. Mechanical Ventilation for Severe Asthma. — Leatherman J. Chest. 2015.
47. Mechanical Ventilation for Severe Asthma. — Leatherman J. Chest. 2015.
48. Invasive Respiratory Support in Critical Pediatric Asthma. — Newth CJL, Ross PA. Respiratory Care. 2025.
49. Invasive Respiratory Support in Critical Pediatric Asthma. — Newth CJL, Ross PA. Respiratory Care. 2025.